Persons with dispensed medicines; age and sex
| Sex | Ages | Medicine group (ATC) | Periods | Persons with medicines, relative (%) |
|---|---|---|---|---|
| Total male and female | Total age | A Alimentary tract and metabolism | 2024* | 21.79 |
| Total male and female | Total age | A16 Other aliment.tract/metabol.products | 2024* | 0.01 |
| Total male and female | Total age | A16A Oth.aliment.tract and metabol.prod. | 2024* | 0.01 |
| Total male and female | Total age | C02A Antiadren.agents, centrally acting | 2024* | 0.07 |
| Total male and female | Total age | C02C Antiadren.agents, peripher. acting | 2024* | 0.24 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2024* | 18.69 |
| Total male and female | Total age | J01C Beta-lactam antibact., penicillins | 2024* | 11.21 |
| Total male and female | Total age | J01D Other beta-lactam antibacterials | 2024* | 0.12 |
| Total male and female | Total age | J01G Aminoglycoside antibacterials | 2024* | 0.01 |
| Total male and female | Total age | J01M Quinolone antibacterials | 2024* | 1.61 |
| Total male and female | Total age | J01R Combinations of antibacterials | 2024* | 0.00 |
| Total male and female | Total age | J01X Other antibacterials | 2024* | 4.22 |
| Total male and female | Total age | J04 Antimycobacterials | 2024* | 0.05 |
| Total male and female | Total age | J05A Direct acting antivirals | 2024* | 0.72 |
| Total male and female | Total age | J07A Bacterial vaccines | 2024* | 0.95 |
| Total male and female | Total age | J07C Bacterial and viral vaccines,combi. | 2024* | 0.00 |
| Total male and female | Total age | M03A Muscle relaxants, peripheral.acting | 2024* | 0.05 |
| Total male and female | Total age | M03B Muscle relaxants, centrally acting | 2024* | 0.12 |
| Total male and female | Total age | M03C Muscle relaxants, directly acting | 2024* | 0.00 |
| Total male and female | 0 to 14 years | A Alimentary tract and metabolism | 2024* | 5.64 |
| Total male and female | 0 to 14 years | A16 Other aliment.tract/metabol.products | 2024* | 0.02 |
| Total male and female | 0 to 14 years | A16A Oth.aliment.tract and metabol.prod. | 2024* | 0.02 |
| Total male and female | 0 to 14 years | C02A Antiadren.agents, centrally acting | 2024* | 0.06 |
| Total male and female | 0 to 14 years | C02C Antiadren.agents, peripher. acting | 2024* | 0.00 |
| Total male and female | 0 to 14 years | J01 Antibacterials for systemic use | 2024* | 14.22 |
| Total male and female | 0 to 14 years | J01C Beta-lactam antibact., penicillins | 2024* | 11.76 |
| Total male and female | 0 to 14 years | J01D Other beta-lactam antibacterials | 2024* | 0.01 |
| Total male and female | 0 to 14 years | J01G Aminoglycoside antibacterials | 2024* | 0.00 |
| Total male and female | 0 to 14 years | J01M Quinolone antibacterials | 2024* | 0.08 |
| Total male and female | 0 to 14 years | J01R Combinations of antibacterials | 2024* | 0.00 |
| Total male and female | 0 to 14 years | J01X Other antibacterials | 2024* | 0.84 |
| Total male and female | 0 to 14 years | J04 Antimycobacterials | 2024* | 0.02 |
| Total male and female | 0 to 14 years | J05A Direct acting antivirals | 2024* | 0.07 |
| Total male and female | 0 to 14 years | J07A Bacterial vaccines | 2024* | 0.06 |
| Total male and female | 0 to 14 years | J07C Bacterial and viral vaccines,combi. | 2024* | 0.00 |
| Total male and female | 0 to 14 years | M03A Muscle relaxants, peripheral.acting | 2024* | 0.00 |
| Total male and female | 0 to 14 years | M03B Muscle relaxants, centrally acting | 2024* | 0.02 |
| Total male and female | 0 to 14 years | M03C Muscle relaxants, directly acting | 2024* | 0.00 |
| Total male and female | 15 to 24 years | A Alimentary tract and metabolism | 2024* | 6.01 |
| Total male and female | 15 to 24 years | A16 Other aliment.tract/metabol.products | 2024* | 0.01 |
| Total male and female | 15 to 24 years | A16A Oth.aliment.tract and metabol.prod. | 2024* | 0.01 |
| Total male and female | 15 to 24 years | C02A Antiadren.agents, centrally acting | 2024* | 0.05 |
| Total male and female | 15 to 24 years | C02C Antiadren.agents, peripher. acting | 2024* | 0.01 |
| Total male and female | 15 to 24 years | J01 Antibacterials for systemic use | 2024* | 13.67 |
| Total male and female | 15 to 24 years | J01C Beta-lactam antibact., penicillins | 2024* | 7.54 |
| Total male and female | 15 to 24 years | J01D Other beta-lactam antibacterials | 2024* | 0.19 |
| Total male and female | 15 to 24 years | J01G Aminoglycoside antibacterials | 2024* | 0.00 |
| Total male and female | 15 to 24 years | J01M Quinolone antibacterials | 2024* | 0.67 |
| Total male and female | 15 to 24 years | J01R Combinations of antibacterials | 2024* | 0.00 |
| Total male and female | 15 to 24 years | J01X Other antibacterials | 2024* | 2.79 |
| Total male and female | 15 to 24 years | J04 Antimycobacterials | 2024* | 0.03 |
| Total male and female | 15 to 24 years | J05A Direct acting antivirals | 2024* | 0.38 |
| Total male and female | 15 to 24 years | J07A Bacterial vaccines | 2024* | 0.80 |
| Total male and female | 15 to 24 years | J07C Bacterial and viral vaccines,combi. | 2024* | 0.00 |
| Total male and female | 15 to 24 years | M03A Muscle relaxants, peripheral.acting | 2024* | 0.00 |
| Total male and female | 15 to 24 years | M03B Muscle relaxants, centrally acting | 2024* | 0.03 |
| Total male and female | 15 to 24 years | M03C Muscle relaxants, directly acting | 2024* | 0.00 |
| Total male and female | 25 to 34 years | A Alimentary tract and metabolism | 2024* | 9.76 |
| Total male and female | 25 to 34 years | A16 Other aliment.tract/metabol.products | 2024* | 0.01 |
| Total male and female | 25 to 34 years | A16A Oth.aliment.tract and metabol.prod. | 2024* | 0.01 |
| Total male and female | 25 to 34 years | C02A Antiadren.agents, centrally acting | 2024* | 0.11 |
| Total male and female | 25 to 34 years | C02C Antiadren.agents, peripher. acting | 2024* | 0.02 |
| Total male and female | 25 to 34 years | J01 Antibacterials for systemic use | 2024* | 15.22 |
| Total male and female | 25 to 34 years | J01C Beta-lactam antibact., penicillins | 2024* | 8.88 |
| Total male and female | 25 to 34 years | J01D Other beta-lactam antibacterials | 2024* | 0.22 |
| Total male and female | 25 to 34 years | J01G Aminoglycoside antibacterials | 2024* | 0.00 |
| Total male and female | 25 to 34 years | J01M Quinolone antibacterials | 2024* | 0.91 |
| Total male and female | 25 to 34 years | J01R Combinations of antibacterials | 2024* | 0.00 |
| Total male and female | 25 to 34 years | J01X Other antibacterials | 2024* | 3.24 |
| Total male and female | 25 to 34 years | J04 Antimycobacterials | 2024* | 0.05 |
| Total male and female | 25 to 34 years | J05A Direct acting antivirals | 2024* | 0.78 |
| Total male and female | 25 to 34 years | J07A Bacterial vaccines | 2024* | 0.99 |
| Total male and female | 25 to 34 years | J07C Bacterial and viral vaccines,combi. | 2024* | 0.00 |
| Total male and female | 25 to 34 years | M03A Muscle relaxants, peripheral.acting | 2024* | 0.00 |
| Total male and female | 25 to 34 years | M03B Muscle relaxants, centrally acting | 2024* | 0.05 |
| Total male and female | 25 to 34 years | M03C Muscle relaxants, directly acting | 2024* | 0.00 |
| Total male and female | 35 to 44 years | A Alimentary tract and metabolism | 2024* | 12.63 |
| Total male and female | 35 to 44 years | A16 Other aliment.tract/metabol.products | 2024* | 0.01 |
| Total male and female | 35 to 44 years | A16A Oth.aliment.tract and metabol.prod. | 2024* | 0.01 |
| Total male and female | 35 to 44 years | C02A Antiadren.agents, centrally acting | 2024* | 0.09 |
| Total male and female | 35 to 44 years | C02C Antiadren.agents, peripher. acting | 2024* | 0.06 |
| Total male and female | 35 to 44 years | J01 Antibacterials for systemic use | 2024* | 16.59 |
| Total male and female | 35 to 44 years | J01C Beta-lactam antibact., penicillins | 2024* | 10.14 |
| Total male and female | 35 to 44 years | J01D Other beta-lactam antibacterials | 2024* | 0.14 |
| Total male and female | 35 to 44 years | J01G Aminoglycoside antibacterials | 2024* | 0.00 |
| Total male and female | 35 to 44 years | J01M Quinolone antibacterials | 2024* | 1.03 |
| Total male and female | 35 to 44 years | J01R Combinations of antibacterials | 2024* | 0.00 |
| Total male and female | 35 to 44 years | J01X Other antibacterials | 2024* | 3.19 |
| Total male and female | 35 to 44 years | J04 Antimycobacterials | 2024* | 0.05 |
| Total male and female | 35 to 44 years | J05A Direct acting antivirals | 2024* | 0.85 |
| Total male and female | 35 to 44 years | J07A Bacterial vaccines | 2024* | 1.02 |
| Total male and female | 35 to 44 years | J07C Bacterial and viral vaccines,combi. | 2024* | 0.00 |
| Total male and female | 35 to 44 years | M03A Muscle relaxants, peripheral.acting | 2024* | 0.01 |
| Total male and female | 35 to 44 years | M03B Muscle relaxants, centrally acting | 2024* | 0.10 |
| Total male and female | 35 to 44 years | M03C Muscle relaxants, directly acting | 2024* | 0.00 |
| Total male and female | 45 to 54 years | A Alimentary tract and metabolism | 2024* | 19.34 |
| Total male and female | 45 to 54 years | A16 Other aliment.tract/metabol.products | 2024* | 0.01 |
| Total male and female | 45 to 54 years | A16A Oth.aliment.tract and metabol.prod. | 2024* | 0.01 |
| Total male and female | 45 to 54 years | C02A Antiadren.agents, centrally acting | 2024* | 0.05 |
| Total male and female | 45 to 54 years | C02C Antiadren.agents, peripher. acting | 2024* | 0.16 |
| Source: CBS. | ||||
Table explanation
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Personal Records Database (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, age and sex.
Data available from: 2006
Status of the figures:
Figures for 2024 are provisional, figures for previous years are final.
Changes as of December 18, 2025:
- Provisional figures for 2024 have been added, provisional figures of 2023 have been made definite.
- Figures for 2024 do not include DDD's as they are insufficiently reliable.
When will new figures be published?
New figures will be published in the last quarter of 2026.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.